Flexion Therapeutics

Flexion Therapeutics is a biopharmaceutical company that specializes in the development and commercialization of novel, local therapies. The company's primary focus is on the treatment of musculoskeletal conditions, particularly osteoarthritis.

History

Founded in 2007, Flexion Therapeutics is headquartered in Burlington, Massachusetts. The company was established with the aim of developing innovative and sustained therapies for diseases affecting the musculoskeletal system.

Products

Flexion Therapeutics' flagship product is Zilretta (triamcinolone acetonide extended-release injectable suspension), which is the first and only FDA-approved extended-release, intra-articular therapy for patients confronting osteoarthritis-related knee pain. Zilretta employs proprietary microsphere technology combining triamcinolone acetonide — a commonly administered, short-acting corticosteroid — with a poly lactic-co-glycolic acid (PLGA) matrix.

Research and Development

Flexion Therapeutics is committed to ongoing research and development in the field of musculoskeletal conditions. The company is currently investigating the potential of FX201, a gene therapy candidate for the treatment of osteoarthritis.

See Also

• Biopharmaceutical
• Osteoarthritis
• Gene therapy

References

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian